Login

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
Q3 FY2021
As of Sep 30, 2021
Q2 FY2021
As of Jun 30, 2021
Q1 FY2021
As of Mar 31, 2021
Q4 FY2020
As of Dec 31, 2020
Q3 FY2020
As of Sep 30, 2020
Q2 FY2020
As of Jun 30, 2020
Q1 FY2020
As of Mar 31, 2020
Q4 FY2019
As of Dec 31, 2019
Q3 FY2019
As of Sep 30, 2019
Q2 FY2019
As of Jun 30, 2019
Q1 FY2019
As of Mar 31, 2019
Q3 FY2018
As of Oct 31, 2018
Q2 FY2018
As of Jul 31, 2018
Q1 FY2018
As of Apr 30, 2018
ASSETS
Current assets
Cash and cash equivalents
Short-term investments
Accounts receivable, net
Inventory
Assets held for sale
Prepaid expenses and other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Intangible assets, net
Goodwill
Other assets
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable and accrued expenses
Other current liabilities
Current portion of long-term note payable
Deferred revenue
Liabilities held for sale
Total current liabilities
Common stock warrant liability
Operating lease liabilities
Other long-term liabilities
Long-term notes payable
Finance lease liabilities
Total liabilities
STOCKHOLDERS’ EQUITY
Common stock – $.001 par value; 250,000,000 shares authorized; 7,325,006 and 7,258,186 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support